You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Foundayo™ (orforglipron) approved, and is it available?
Orforglipron was FDA approved on April 1, 2026, and is now available through LillyDirect®, telehealth providers, and US retail pharmacies.
See important safety information, including boxed warning, in the attached prescribing information.
What Is Orforglipron and Is It Approved in the United States?
Foundayo™ contains orforglipron, a glucagon-like peptide-1 (GLP‑1) receptor agonist for once‑daily oral administration, with or without food.1
Orforglipron was approved by the US Food and Drug Administration (FDA) on April 1, 2026, for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with
Orforglipron is now available through LillyDirect®, telehealth providers, and US retail pharmacies.3
Enclosed Prescribing Information
References
1Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
2FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Press release. Eli Lilly and Company; April 1, 2026. Accessed April 1, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
3Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. Press release. Eli Lilly and Company; April 9, 2026. Accessed April 9, 2026. https://investor.lilly.com/news-releases/news-release-details/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-weight-loss
Date of Last Review: April 09, 2026